Emory University has spun out antiviral assets from its in-house drug discovery institute into a new not-for-profit company. Drug Innovation Ventures at Emory LLC, known as DRIVE, expects to both speed translational development by operating outside the university's cumbersome decision-making structure, and retain more of the value from fruits of the university's screening and medicinal chemistry work.

DRIVE is starting with a license to a pending patent covering a novel class of nucleoside analogs for infections caused by single-stranded RNA viruses such as respiratory syncytial virus